Literature DB >> 21486904

Genotype-phenotype correlations in early onset ataxia with ocular motor apraxia and hypoalbuminaemia.

Akio Yokoseki1, Tomohiko Ishihara, Akihide Koyama, Atsushi Shiga, Mitsunori Yamada, Chieko Suzuki, Yoshiki Sekijima, Kyoko Maruta, Miyuki Tsuchiya, Hidetoshi Date, Tatsuya Sato, Masayoshi Tada, Takeshi Ikeuchi, Shoji Tsuji, Masatoyo Nishizawa, Osamu Onodera.   

Abstract

Early onset ataxia with ocular motor apraxia and hypoalbuminaemia/ataxia-oculomotor apraxia 1 is a recessively inherited ataxia caused by mutations in the aprataxin gene. We previously reported that patients with frameshift mutations exhibit a more severe phenotype than those with missense mutations. However, reports on genotype-phenotype correlation in early onset ataxia with ocular motor apraxia and hypoalbuminaemia are controversial. To clarify this issue, we studied 58 patients from 39 Japanese families, including 40 patients homozygous for c.689_690insT and nine patients homozygous or compound heterozygous for p.Pro206Leu or p.Val263Gly mutations who were compared with regard to clinical phenotype. We performed Kaplan-Meier analysis and log-rank tests for the ages of onset of gait disturbance and the inability to walk without assistance. The cumulative rate of gait disturbance was lower among patients with p.Pro206Leu or p.Val263Gly mutations than among those homozygous for the c.689_690insT mutation (P=0.001). The cumulative rate of inability to walk without assistance was higher in patients homozygous for the c.689_690insT mutation than in those with p.Pro206Leu or p.Val263Gly mutations (P=0.004). Using a Cox proportional hazards model, we found that the homozygous c.689_690insT mutation was associated with an increased risk for onset of gait disturbance (adjusted hazard ratio: 6.60) and for the inability to walk without assistance (adjusted hazard ratio: 2.99). All patients homozygous for the c.689_690insT mutation presented ocular motor apraxia at <15 years of age. Approximately half the patients homozygous for the c.689_690insT mutation developed cognitive impairment. In contrast, in the patients with p.Pro206Leu or p.Val263Gly mutations, only ∼50% of the patients exhibited ocular motor apraxia and they never developed cognitive impairment. The stepwise multivariate regression analysis using sex, age and the number of c.689_690insT alleles as independent variables revealed that the number of c.689_690insT alleles was independently and negatively correlated with median motor nerve conduction velocities, ulnar motor nerve conduction velocities and values of serum albumin. In the patient with c.[689_690insT]+[840delT], p.[Pro206Leu]+[Pro206Leu] and p.[Pro206Leu]+[Val263Gly] mutations, aprataxin proteins were not detected by an antibody to the N-terminus of aprataxin. Furthermore Pro206Leu and Val263Gly aprataxin proteins are unstable. However, the amount of the 689_690insT aprataxin messenger RNA was also decreased, resulting in more dramatic reduction in the amount of aprataxin protein from the c.689_690insT allele. In conclusion, patients with early onset ataxia with ocular motor apraxia and hypoalbuminaemia homozygous for the c.689_690insT mutation show a more severe phenotype than those with a p.Pro206Leu or p.Val263Gly mutation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21486904     DOI: 10.1093/brain/awr069

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  15 in total

1.  Pitfalls in ataxia with ocular motor apraxia type 1: pseudodominant inheritance and very late onset.

Authors:  Chloé Laurencin; Mathieu Anheim; Lise Larrieu; Caroline Tilikete; Michel Koenig; Stéphane Thobois
Journal:  J Neurol       Date:  2015-04-07       Impact factor: 4.849

2.  Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway.

Authors:  Beatriz Garcia-Diaz; Emanuele Barca; Andrea Balreira; Luis C Lopez; Saba Tadesse; Sindhu Krishna; Ali Naini; Caterina Mariotti; Barbara Castellotti; Catarina M Quinzii
Journal:  Hum Mol Genet       Date:  2015-05-14       Impact factor: 6.150

3.  Clinical, Biomarker, and Molecular Delineations and Genotype-Phenotype Correlations of Ataxia With Oculomotor Apraxia Type 1.

Authors:  Mathilde Renaud; Maria-Céu Moreira; Bondo Ben Monga; Diana Rodriguez; Rabab Debs; Perrine Charles; Malika Chaouch; Farida Ferrat; Chloé Laurencin; Laurent Vercueil; Martial Mallaret; Abderrahim M'Zahem; Lamia Ali Pacha; Meriem Tazir; Caroline Tilikete; Elisabeth Ollagnon; François Ochsner; Thierry Kuntzer; Hans H Jung; Jean-Marie Beis; Jean-Claude Netter; Atbin Djamshidian; Mattew Bower; Armand Bottani; Richard Walsh; Sinead Murphy; Thomas Reiley; Éric Bieth; Filip Roelens; Bwee Tien Poll-The; Charles Marques Lourenço; Laura Bannach Jardim; Rachel Straussberg; Pierre Landrieu; Emmanuel Roze; Stéphane Thobois; Jean Pouget; Claire Guissart; Cyril Goizet; Alexandra Dürr; Christine Tranchant; Michel Koenig; Mathieu Anheim
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

Review 4.  Update on clinical aspects and treatment of selected vitamin-responsive disorders II (riboflavin and CoQ 10).

Authors:  Rita Horvath
Journal:  J Inherit Metab Dis       Date:  2012-01-10       Impact factor: 4.982

5.  Diminished OPA1 expression and impaired mitochondrial morphology and homeostasis in Aprataxin-deficient cells.

Authors:  Jin Zheng; Deborah L Croteau; Vilhelm A Bohr; Mansour Akbari
Journal:  Nucleic Acids Res       Date:  2019-05-07       Impact factor: 16.971

Review 6.  Polynucleotide kinase-phosphatase (PNKP) mutations and neurologic disease.

Authors:  Lavinia C Dumitrache; Peter J McKinnon
Journal:  Mech Ageing Dev       Date:  2016-04-26       Impact factor: 5.432

Review 7.  Overview of Albumin Physiology and its Role in Pediatric Diseases.

Authors:  Charles B Chen; Bilasan Hammo; Jessica Barry; Kadakkal Radhakrishnan
Journal:  Curr Gastroenterol Rep       Date:  2021-07-02

8.  Ataxia Oculomotor Apraxia Type 1 in the Siblings of a Family: A Novel Mutation.

Authors:  Parvaneh Karimzadeh; Simin Khayatzadeh Kakhki; Shaghayegh Sadat Esmail Nejad; Masood Houshmand; Mohammad Ghofrani
Journal:  Iran J Child Neurol       Date:  2017

9.  Complete APTX deletion in a patient with ataxia with oculomotor apraxia type 1.

Authors:  Rick van Minkelen; Miriam Guitart; Conxita Escofet; Grace Yoon; Peter Elfferich; Galhana M Bolman; Robert van der Helm; Raoul van de Graaf; Ans M W van den Ouweland
Journal:  BMC Med Genet       Date:  2015-08-19       Impact factor: 2.103

10.  Ataxia with Oculomotor Apraxia Type 1 without Oculomotor Apraxia: A Case Report.

Authors:  Minwoo Lee; Nan Young Kim; Jin Young Huh; Young Eun Kim; Yun Joong Kim
Journal:  J Clin Neurol       Date:  2015-11-04       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.